KALA BIO Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Avi Minkowitz

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	6.4yrs
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Oct 20

Kala Pharmaceuticals to execute reverse stock split

Kala Pharmaceuticals (NASDAQ:KALA) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s (KALA) issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. The split will reduce the number of shares of common stock outstanding from 73,208,140 shares to ~1,464,163 shares, subject to adjustment for the rounding up of fractional shares. The stock will will begin trading on a split-adjusted basis when the market opens on Friday, October 21, 2022. KALA shares are down over 2% premarket

Seeking Alpha • Aug 10

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.36 (+36.8% Y/Y) and the consensus Revenue Estimate is $2.02M (-33.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

CEO

Avi Minkowitz (37 yo)

less than a year

Permanencia

Mr. Avi Minkowitz is CEO & CFO at KALA BIO, Inc. from February 2, 2026. He is Director of KALA BIO, Inc. from January 2026. Mr. Minkowitz serves as Director at International Star, Inc. since October 20, 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mary Reumuth	Treasurer & Secretary	12.3yrs	US$1.38m	sin datos
Avi Minkowitz	CEO, CFO & Director	less than a year	sin datos	sin datos
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	sin datos	sin datos
Jill Steier	Executive Director of Investor Relations & Corporate Communications	4.8yrs	sin datos	sin datos
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	8.8yrs	sin datos	sin datos
Francis Mah	Chief Medical Advisor	3.2yrs	sin datos	sin datos
Josiah Craver	Senior VP & Corporate Controller	4.1yrs	sin datos	sin datos
Carl Rennie	Executive Director of Account Management	8yrs	sin datos	sin datos
Patrick Bedell	Executive Director of Trade & Alternate Channels	8yrs	sin datos	sin datos

6.4yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de KALA es experimentado (6.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Avi Minkowitz	CEO, CFO & Director	less than a year	sin datos	sin datos
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	sin datos	sin datos
Jonathan Silverstein	Board Observer	10.1yrs	sin datos	sin datos
Peter Hutt	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ronald Krall	Member of Scientific Advisory Board	no data	sin datos	sin datos
Bennett Shapiro	Member of Scientific Advisory Board	no data	sin datos	sin datos
Colin Gardner	Member of Scientific Advisory Board	no data	sin datos	sin datos
Brendan Purdy	Independent Director	less than a year	sin datos	sin datos
Yonatan Colman	Independent Director	less than a year	sin datos	sin datos
Chaim Berger	Independent Director	less than a year	sin datos	sin datos
Hillel Posen	Independent Director	less than a year	sin datos	sin datos

0.3yrs

Permanencia media

41.5yo

Promedio de edad

Junta con experiencia: La junta directiva de KALA no se considera experimentada (0.3 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/21 17:50
Precio de las acciones al final del día	2026/05/21 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

KALA BIO, Inc. está cubierta por 7 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Tazeen Ahmad	BofA Global Research
Biren Amin	Jefferies LLC
Christopher Neyor	J.P. Morgan

KALA BIO Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

Chairman notifies of intention to sell stock

KALA BIO, Inc. Announces Chief Executive Officer Changes

Recent updates

KALA BIO, Inc. announced delayed annual 10-K filing

Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent

Kala Bio Announces Launch Of First Commercial AI Product

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

Kala Bio, Inc. Receives Notice of Nasdaq Minimum Bid Price Non-Compliance

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $9.99909 million.

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO, Inc. announced delayed 10-Q filing

KALA BIO, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

KALA BIO, Inc. announced that it expects to receive $0.375 million in funding

KALA BIO, Inc. Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Financial position

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect

Chairman notifies of intention to sell stock

New major risk - Revenue and earnings growth

New major risk - Share price stability

New minor risk - Share price stability

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. announced that it has received $10.749667 million in funding

KALA BIO, Inc. announced that it expects to receive $10.749667 million in funding

New major risk - Share price stability

Price target decreased by 15% to US$16.50

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Consensus revenue estimates fall by 27%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Price target decreased to US$5.25

CEO

Equipo directivo

Miembros de la Junta

Análisis de la empresa y estado de los datos financieros

Fuentes de datos

Modelo de análisis y copo de nieve

Métricas industriales y sectoriales

Fuentes analistas